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Abstract

The mortality rate of aneurysmal subarachnoid hemorrhage (aSAH) can be
as high as 70 percent. Of patients whom survive, 25-30 percent develop
some degree of vasospasm up to 21 days after initial onslaught. Vasospasm
is the second leading cause of death and disability in patients with
subarachnoid hemorrhage (SAH). The American Stroke Association (ASA)
guidelines for management of SAH recommend oral Nimodipine and
endovascular treatments to limit detrimental effects of vasospasm. In
patients with severe, unrelenting vasospasm, outcomes within an academic,
community Magnet® hospital have shown promising results when
implementing alternative therapies after radiographic evidence that
vasospasm is not resolving by endovascular intervention. This presentation
details the pathophysiology of vasospasm, outlines ASA guidelines for
treatment of aSAH, and uses two case studies to present alternative
treatment options including targeted temperature management, intravenous
Milrinone, low dose Nicardipine infusions, and intra-thecal medication
administration.

Objectives

1. Outline the published American Stroke Association guidelines for the
management of aSAH.
2. D
 iscuss the pathophysiology of vasospasm in the aSAH patient.
3. D
 etail two case studies that demonstrate that the addition of targeted
temperature management cooling, intravenous Milrinone, intravenous
low-dose Nicardipine and intra-thecal medication administration may be
adjunct therapies in angiographic vasospasm limiting the severity of the
spasm and improving patient outcomes.
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Management of aSAH

1. aSAH affects 30,000 people annually in the
United States
a. Location of aneurysm is a prognostication
of survival and potential neurological deficits
2. C
 linical manifestations and diagnosis of aSAH
a. Complaint of “worst headache of my life”
b. Sentinel bleed or warning leak
3. S
 urgical and endovascular methods for
treatment of ruptured aneurysms
a. Surgical clipping in patients with large
(>50 mL)
b. Surgical clipping recommended for wide
base aneurysm
c. Endovascular coiling patients > 70 years
of age
d. E
 ndovascular coiling consideration in
aneurysms if in the basilar apex
4. M
 anagement of cerebral vasospasm and
delayed cerebral ischemia
a. Oral Nimodipine should be administered to
all patients with aSAH
b. Maintenance of euvolemia and circulating
blood volume
c. Induction of hemodynamic augmentation to
improve cerebral perfusion
d. C
 erebral angioplasty and/or intra-arterial
vasodilation

Management of Cerebral Vasospasm
and Delayed Cerebral Ischemia

1. Any neurological deterioration presumed to be
related to ischemia that lasts for more than
one hour
a. Angiographic narrowing of arteries
b. Elevated cerebral blood flow velocities
c. Occurs 7 to 10 days after rupture and
resolves spontaneously after 21 days
d. M
 ajor cause of death and disability
2. O
 xyhemoglobiin comes in contact with the
abluminal side of a vessel
3. D
 epletion of nitric oxide causes cerebral
vasoconstriction
4. F
 ree radical oxidation of bilirubin stimulates
vasoconstriction
5. Inflammation and leukocyte adherence to the
vascular endothelium
6. Presence of cytokine proteins in the vasculature

Case Studies

1

Hunt and Hess grade 4, modified Fisher 4 subarachnoid
hemorrhage secondary to a
ruptured left anterior commu
nicating artery aneurysm in a
29-year-old female
a. Coil assisted embolization
with secured aneurysm
b. Hemi-craniotomy with external
ventricular device (EVD)
c. Symptomatic vasospasm
on day #4
		• Intra-arterial Verapamil
administration
d. S
 ymptomatic vasospasm of
internal carotid arteries and
middle cerebral arteries
		• Daily to Interventional Radiology
e. Vasospasm/cerebral edema
unrelenting leading to adjunct
treatment options
		• Intrathecal nicardipine
		• Serum NA goal 155-160
		• Intravascular cooling
		• Low dose Nicardipine infusion
		• Intravenous Milrinone infusion
		• Medically induced (pentobarbital)
coma on day #16
f. D
 ischarged to rehabilitation
hospital after 38 days

2

Hunt and Hess grade 3, modified fisher 4 subarachnoid
hemorrhage secondary to
ruptured posterior communicating aneurysm rupture in a
57-year-old female
a. Aneurysm clipped on day #1
b. Vasospasm on hospital day #4
		• Middle cerebral artery and
bilateral internal carotid artery
c. Interventional Radiology for IV
Verapamil X 10 consecutive days
d. R
 eceived continuous low dose
Nicardipine as an adjunct therapy
e. Received intravascular targeted
temperature management
f. C
 hemically paralyzed to optimize
ventilation and impact shiver
threshold
g. Tracheostomy and percutaneous
endoscopic gastrostomy (PEG)
on day #28
h. Transfer to medical-surgical unit
on hospital day #33
i. Transfer to inpatient rehabilitation
unit on day #45
j. D
 ischarge home with husband on
day #66
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